Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Ok. So now the company will reverse split and dilute back up to 250 million shares so they can pay for these delayed phase 3s. Seen it 1000 times in OTC biotech.
Hopefully something good. Its their second one in two months.
Todays presentation offered nothing new. In fact, large portions were word for word verbatim from presentations that they did 8 plus months ago. How many times are they going to repeat the "why invest in tapimmune now?" Slide??
Ive followed/held TPIV for over two years now and the word that is always associated with them is "potential"
That will only get you so far.
As with any biotech the market wants binary events. Aka get some actual data from Phase II trials. Its great that they achieved "robust immune response" in phase ones but that is OLD NEWS.
What are we all waiting for? Obviously proof of efficacy in phase 2s. It seems like ive been waiting forever. Might as well wait a little more.
Unfortunately this is what happens when people are waiting on a collaboration announcement for the better 7 months. It lands with a resounding thud.
Nonetheless still holding long. Green days ahead.
I dont think you understand what the phrase missing the boat means
So i guess that means he has 90 days to get back on the boat LMAO
Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer
Estimated enrollment: 80
Study Start Date: April 2016
Estimated Study Completion Date: December 2019
Estimated Primary Completion Date: June 2017 (Final data collection date for primary outcome measure)
https://clinicaltrials.gov/ct2/show/NCT02593227?term=Tapimmune&rank=1
Lmao I don't think you have to be "savvy" to realize a compound must actually exist before it can be administered lol
But heres the thing. The collaboration was originally announced in september 2015 that it was anticipated to be announced by the end of 4th quarter 2015 so it has been much longer than the few days or weeks that you are claiming
I say that is highly unlikely as that is material information that would have to be disclosed
Thx. Edited my original comment. My phone formatting messed it up
I'd love to hear what they have to say.
Well to be fair there are plenty of times where sheff doesnt post his buys/sells until sometime after market close.
Has he done it that way because he was just busy or because he wanted to make sure his order filled isn't particularly important to me because naturally i don't just blindly follow his lead
Lmao. People have been saying that for a year and a half. Gotta love the OTC.
He is being very well compensated for his work. Shareholders have the right to express any opinion as long as it adheres to the forum rules right?
Yeah i listened as well. Anyone invested in tpiv should at least monitor the progress of gale. Judging by the online chatter alot do.
Im honestly not even expecting anything overly impressive with the BP partner trial (speaking in terms of things like upfront payments NOT in reference to the actual clinical results)Every biotech under the sun has a trial in combination with a PD1. As an example search for "keytruda" on clinicaltrials.gov. You are met with a whopping 255 studies (227 open).
Um, i am well aware of all those milestones as they have been repeated ad nauseam.
Continuing to wait for the first patient to be dosed in a phase II study
For all the progress this company has made whether it be raising capital, securing intellectual property or strengthening its board the bottom line is that it has been selling itself as a multiple phase two ready company since late 2014
Those of us that have tracked,followed,flipped etc this ticker are not upset that its a matter of simply another quarter has passed without commencement they are upset because of the lack of clinical progression for a year and a half
Their website is an outdated joke and glynn only seams to be interested in communicting via interview with small time outlets like stocknewsnow.com
The only reason i am still holding is the science that has been validated (so far anyways) by the dod grant and mayo clinic/edith perez connections it is not because of my faith in management
Of course the annual report will be filed late. Thats just how glynn roles
Um, what are you talking about? ZERO phase two trials have been initiated.
You know that right? LOL
No, people don't need to calm down about timelines. True longs know that this company has been talking about initiating phase IIs for a LONG time now.
Here is an interview where glen discusses the "near term" initiation of phase 2.
Honestly, I am underwhelmed by this. They need to start enrolling patients in some of these phase 2s already. They have been touting themselves as a multiple phase two study ready company since late 2014.
There has been nothing from the last two conferences. Before the new pipeline posted today the most recent presentation was from December 2015 and it was outdated as they reference trial expectations for 4Q2015 multiple times.
They say that every Presentation PR they put out.
http://finance.yahoo.com/news/tapimmune-present-source-capitals-2016-133000009.html
http://finance.yahoo.com/news/tapimmune-present-biotech-showcase-2016-141500083.html
Hopefully at least this time they will bother to make the powerpoints public. The corporate presentations they currently have available are outdated
Damn, this place is a ghost town
Ok the first trial on the list is only a registry. The second is involving solely a checkpoint inhibitor. I could go on one by one on how they differ from Tapimmune's trials but whats the point really. You have the unique ability of copying and pasting but lack the ability to read and understand
That is clearly a trial that hasn't been specifically identified yet. Even if TPIV 200 will be used for different indications (and we all know that is the plan) they are not going to be all be lumped in as a part of the NCT02593227 trial that you keep copying and pasting. It will be a separate trial entirely with its own parameters and outcome measures etc.
Do you even read the links that you post? It clearly says triple negative breast cancer
Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer
https://clinicaltrials.gov/ct2/show/NCT02593227?term=Tapimmune&rank=1
I remember when that first aired over a year ago. Almost hard to believe we are still waiting on phase 2 initiation. At least there were chances to flip along the way
Looks like they changed the primary outcome measures as well. the expected average duration of the study was increased from 60 to 118 days.
Yeah, still not seeing it.
Directly from the trial:
Estimated Enrollment: 15
Study Start Date: July 2015
Estimated Study Completion Date: December 2016
Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
where did you get those days from? The clinical trial link you provided states that Dec 2016 is the estimated primary completion date
If anyone is interested here is a corporate presentation from Dec. 2014.
http://www.tapimmune.com/wp-content/uploads/2014/12/TapImmune-PPT-12142014.pptx
TPIV 100 & 200 have been Phase II "ready" since then.
Considering he is a well diversified billionaire probably not. Unfortunately we all don't have that luxury
That is generally true except the press release specifically stated " The presentation will provide an update on clinical programs and pipeline development."
When is the last time shareholders were updated? The December presentation I believe.
Not to mention the company website www.tapimmune.com is incredibly outdated. The most recent corporate presentation posted on there mentions several times phase II initiations expected in Q3 2015.
I urge all investors to spend 10 minutes and check the website out. This is actually on their CURRENT pipeline "TPIV100 is completing Phase 1 with Phase lb/ll scheduled to start in Q4 2014."
That is just one example. Literally the entire site is littered with missed milestones.
I'm still holding since thankfully I am still green but the fact remains that the company is starting to MISS announced projected milestones. Sure, they may be self-imposed but if it is stated as an expectation they really should update shareholders when they are missed.
So, have any of the phase 2 studies actually started yet? (Mayo clinic one in particular)
Ive been to all the usual sources (clinicaltrials.gov, mayo clinic, company website, etc) and I haven't found evidence that they have. Numerous tapimmune PRs and presentations state antipated start time during the 3rd and 4th qtr 2015.
Whats the hold up?
New(?) poster
Hey everyone. This is on the tapimmune website. http://www.tapimmune.com/wp-content/uploads/2016/01/TPIV-Fact-Sheet-TapImmune.pdf
Maybe its the poster used for the most recent presentation ( pure speculation on my part). The cash balance is as of 1/8/16 so I believe it is the most current company synopsis. I did notice that for the upcoming milestones they used "next 3-12 months" instead of within next 12 months. Perhaps we might have to temper our expectations when the partnership will be announced.
Does anyone see anything intersting i might have missed?